Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 9, 2024
Product Development
How to establish causality via patient observation
Strategies to find targets in patient data are largely grounded in genetics, but the toolbox is diversifying, and increasingly longitudinal
BioCentury | Oct 7, 2024
Discovery & Translation
Causal biology in the age of big data
Where do you start? Patient data might sound more obvious, but human cell-based models have advantages
BioCentury | Sep 5, 2024
Discovery & Translation
AI for target discovery: the start of a long road
Back to School 2024: Investments in AI in drug discovery pick up, as the picture starts to form of how target discovery may benefit
BioCentury | May 7, 2024
Emerging Company Profile
Xaira’s $1B AI play: de novo antibodies now, causal biology to follow
Xaira will initially aim Baker tech at validated targets; functional genomics and patient data are its plan for “breaking the system” for target discovery
BioCentury | Mar 9, 2024
Discovery & Translation
Science spotlight: Elixirgen’s full-length dystrophin gene therapy, Insilico’s TNIK inhibitor and more
BioCentury’s roundup of translational innovations
BioCentury | Oct 6, 2016
Distillery Therapeutics
Therapeutics: TRAF2 and NCK interacting kinase (TNIK)
Items per page:
1 - 9 of 9